Australian cancer researchers are the first to establish a next-generation gene-editing tool for modeling and interrogating human disease.

In the rapidly evolving field of genetic engineering, few names resonate as profoundly as George Church, a geneticist at Harvard University. Known for his groundbreaking work in genomics, Church has ...

The UK’s Medicines and Healthcare Regulatory Agency (MHRA) approved Casgevy for sickle cell disease in 2023, followed by ...

People in England to benefit from groundbreaking one-off gene therapy for severe sickle cell disease approved by NICE ...

Australian researchers have successfully introduced an improved version of Cas12a gene-editing enzyme in mice.

Around 1,700 people could be eligible for the one-time treatment, which is seen as a less risky alternative to a donor stem ...

January 31, 2025 expert reaction to NICE final draft guidance on exagamglogene autotemcel (exa-cel) for severe sickle cell disease . Scientists comment on final draft guidance fro ...

NHS patients with sickle cell disease will be able to benefit from a groundbreaking gene-editing treatment that offers the prospect of a cure for the condition. The one-off gene therapy, known as ...

A £1.65 million treatment has been approved for use for some NHS patients, offering some with an inherited blood disorder ...

Unlocking Plastic Recycling Since their widespread adoption by the manufacturing industry in the 1960s, plastics have become an omnipresent material in our daily lives. They are also the cause of very ...

Australian cancer researchers are the first to establish a next-generation gene-editing tool for modeling and interrogating ...

Australian cancer researchers are the first to establish a next-generation gene-editing tool for modelling and interrogating human disease.